Finance

Laverock Therapeutics raises £13.5m to develop unique gene silencing platform for programmable advanced therapies

Laverock Therapeutics, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS) platform for all human therapeutic applications, has expanded its seed funding round to £13.5m. This...

View the Online Magazine

Latest Issue

Magazine Archive

Launches

University launches new centre for blood disorder research

The University of York is today (11 July) launching the Centre for Blood Research - a pioneering initiative bringing together for the first time...

An integrated approach is essential to tackle growing drug dependence epidemic

A year on from the launch of the College of Medicine Beyond Pills Campaign, leading doctors, pharmacists, politicians and patients are convening today at...

Lupin Healthcare launches Beclu® (beclometasone dipropionate) certified carbon neutral inhalers for the treatment of asthma in the UK

Lupin Healthcare, the UK-based wholly owned subsidiary of Lupin Limited (Lupin) has announced the UK launch of Beclu® (beclometasone dipropionate) 100 micrograms (mcg) and...

Suppliers Guide

Check out our Suppliers Guide or contact our team and get your company listed

Subscribe

Keep up with what's happening in the industry and subscribe to our weekly newsletter

Events

Get your event seen by potential candidates on the world's leading industry site.

Supply Chain

UK Health Security Agency agrees vaccine deal

The UK Health Security Agency (UKHSA) has agreed a deal for millions of life-saving vaccines to be produced in the UK if a future...

Menarini becomes exclusive distributor for INVOKANA® (canagliflozin) and VOKANAMET® (fixed-dose combination of canagliflozin and metformin) in the UK

A. Menarini Farmaceutica Internazionale SRL (Menarini) has become the exclusive distributor for INVOKANA® (canagliflozin) and VOKANAMET® (a fixed-dose combination of canagliflozin and metformin) in the United...

Outcome Management: The cure for pharma’s toughest trials – by Johannes Müller, co-founder and CEO of Workpath

The pharmaceutical sector is currently grappling with significant challenges that are impacting its operations and long-term viability.  Rising cost pressures due to inflation and...

FDA moves forward with mail-back envelopes for opioid analgesics

The U.S. Food and Drug Administration is requiring manufacturers of opioid analgesics dispensed in outpatient settings to make prepaid mail-back envelopes available to outpatient...

Approvals

Manufacturiung

Finance

Research & Development
Latest

R&D

Evaxion partners with Afrigen Biologics to develop mRNA vaccine against gonorrhea

Evaxion, a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, is collaborating with Afrigen Biologics (Afrigen) to develop a prophylactic vaccine based...
R&D

BioNTech and CEPI to advance mRNA mpox vaccine development

BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) have formed a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for the...
R&D

BARDA partners with ICON for next generation COVID-19 vaccines clinical trial

ICON plc, a healthcare intelligence and clinical research organisation, is partnering with the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the...
R&D

First Wave BioPharma to repurpose Sanofi’s Capeserod for gastrointestinal indications

First Wave BioPharma, a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, has announced an agreement with...
R&D

AbCellera collaborates with Incyte to accelerate discovery and development of therapeutic antibodies in oncology

AbCellera has entered into a strategic collaboration with Incyte to discover and develop therapeutic antibodies in oncology. “We are excited to partner with Incyte, which has...

Appointments

© 2021 Part of the Business Link Magazine Group. Armstrong House, Armstrong Street, Grimsby,
North East Lincolnshire, DN31 2QE

About Us

Popular Category

Editor Picks